🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Terrific paper from Neeraj Agarwal, MD, FASCO Daniel Castellano et al in Clinical Cancer Research re: #abemaciclib in #metastatic #prostatecancer ... full article here: aacrjournals.org/clincancerres/…

Just in ACS Journal Cancer 👉Pts w/ clear cell mRCC #kidneycancer from real world Flatiron database s/p ICI Rx👉 Similar survival w/ cabo + ICI vs. cabo monoRx aligning w/ #CONTACT03 trial results UroToday.com OncoAlert @huntsmangu Umang Swami Neeraj Agarwal, MD, FASCO 👇tinyurl.com/2w79fbt8

Neoadjuvant chemo (NAC) has benefit in OPTICAL and FOxTROT! 👏🏽to all authors! A 🧵 ascopubs.org/doi/10.1200/JC… Jenny Seligmann

Just in Eur Urol Focus 👉🏻Pts w/ synchronous (Dx-Mx ≤ 3 mos) vs metachronous mRCC #kidneycancer treated w/ 1st line ICI Rx ➡️worse clinical outcomes 👇🏻 tinyurl.com/kheb6542 Georges Gebrael Luis A. Meza Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer Genitourinary Cancer Research Team @CityofHope UroToday.com OncoAlert

#PancreaticCancer #ClinicalTrials are necessary to determine whether new treatments are beneficial to people living with the disease. Learn about a multicenter, phase 2 trial looking at a new drug combination: bit.ly/3ILKm7d or email [email protected].

Just in Cancer Cell 👉Validation of the molecular clusters of the IMmotion151 trial in the JAVELIN Renal 101 dataset #kidneycancer: Excellent commentary highlighting these biomarkers by our fellow @chadihc98 👇tinyurl.com/48px5rw8 GU Cancer Research Program @HuntsmanCancer OncoAlert UroToday.com KidneyCAN

Just in JAMA Network Open 👉Our paper on treatment trends and attrition rates for advanced #bladdercancer in the US👉2/3rd of patients did not receive even 2nd-line Rx. Grateful for mentorship by Umang Swami Neeraj Agarwal, MD, FASCO. Link👉 bit.ly/3UHwBgv GU Cancer Research Program @HuntsmanCancer OncoAlert

#AUA24 Amer. Urol. Assn. 👉 Most pts (63%) diagnosed with mCRPC (even in 2023) never received prior NHT. NHT remains most common Rx in 1L mCRPC (even in pts treated with prior NHT). Neeraj Agarwal, MD, FASCO Pedro C Barata, MD MSc FACP OncoAlert UroToday.com PCF Science GU Cancer Research Program @HuntsmanCancer

Just in European Urology Oncology: We present gene expression in denovo vs relapsed (metachronous) mHSPC #ProstateCancer 👉⬆️ inflammatory pathways in denovo vs. ⬆️ AR pathways in relapsed mHSPC Thanks to mentors Umang Swami Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer OncoAlert Link bit.ly/3UTX3nn

Cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma - Enrique Grande MD Anderson Cancer Center ACS Journal Cancer Georges Gebrael Vinay Mathew Thomas Li Haoran, MD, PhD Nicolas Sayegh, MD Umang Swami Neeraj Agarwal, MD, FASCO Benjamin L Maughan oncodaily.com/drugs/69364.ht… #OncoDaily #Oncology

Proud of martin zarba for presenting this #IMDC study. More follow up and patients required but it does highlight the importance of VEGF inhibition in very favorable patients. They are the most sensitive. #hypothesisgenerating #ASCO24 OncoAlert

Ab#4527 ASCO #ASCO24 👉 ascopubs.org/doi/abs/10.120… 👉 In Flatiron Health we showed ⬆️ but suboptimal 1L use of IO-based tx and➕pts alive at 1y following tx discontinuation for mccRCC after 2018 Neeraj Agarwal, MD, FASCO Umang Swami OncoAlert UroToday.com

Heartiest congratulations to Neeraj Agarwal, MD, FASCO and Adriana M Coletta, PhD, MS, RD for Huntsman Cancer Institute Collaborative Award for RO1 grant 👉 randomized trial of creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression

Just in JAMA Network Open 👉 Unacceptablely low rates of NGS testing in metastatic #ProstateCancer #bladdercancer in real world pts (worse in Black & Hispanic pts)Flatiron Health👇Proud of our postdoc, Chadi Chadi Hage Chehade , Yeonjung @yeonjungjohci, George Georges Gebrael & team👇

Today I was thrilled to visit KU Cancer Center The University of Kansas Health System and meet their staff, trainees, and community members to learn about the important research and care they provide in Kansas. Many thanks to Sen. Senator Jerry Moran for his continued leadership in support of #CancerResearch!

Excited to share that our poster was awarded the best poster award in the policy and preventive strategies category! #ESMO24 ESMO - Eur. Oncology Grateful for terrific mentorship from Neeraj Agarwal, MD, FASCO and team Umang Swami Benjamin L Maughan @NeliMUlrich Sumanta K. Pal, MD, FASCO GU Cancer Research Program @HuntsmanCancer UroToday.com OncoAlert

Full house for Tom Powles ‘s presidential talk of the results of the ph3 NIAGARA trial w/ neo-adj durva + gem-cis followed by surgery + adj durva in pts w/ MIBC #bladdercancer 👇🏻 ⭐️ HR 0.68 for EFS (primary endpoint) & 0.75 for OS ⭐️ pCR 37.3% w/ Durva UroToday.com OncoAlert

Take home: For those still using GC x 4 cycles as NAC, practice should change to add Durva to GC pre and 8 cycles post. For those using DDMVAC, similar results can be achieved while saving IO for adjuvant using a risk adapted approach based on pathologic stage.

Wondering about AI in #prostatecancer ? 🤔 Check this poster ➡️Utilizing ChatGPT for Assessing Disease Volume in Patients Li Haoran, MD, PhD ASCO #GU25

Now pannel discussion Anusha MD Li Haoran, MD, PhD Dr. Weijing Sun and Dr. Christine Bestivina KU Cancer Center #MedEd #MedTwitter OncoAlert USMIRC News #سرطان_الدم #المايلوما